Synapse loss is the strongest correlate of cognitive decline in Alzheimer's disease, and synapses are an attractive therapeutic target due to their plastic nature that allows for potential recovery with intervention. We have previously demonstrated in transgenic mice that form senile plaques that dendrites surrounding plaques become dystrophic and lose postsynaptic dendritic spines. Furthermore, we found strong evidence that plaque-associated dendritic changes are mediated by calcineurin, a calcium-dependent phosphatase involved in cell signaling, using in vitro models and genetically encoded inhibitors in mouse models. In this study, we pharmacologically inhibited calcineurin with FK506 treatment to test the hypothesis that calcineurin inhibition will allow recovery of plaque-associated synapse loss. We found that in plaque bearing transgenic mice, short term (1 week) FK506 treatment results in an amelioration of dendritic spine loss. We also observe an effect on spine morphology in wild-type mice with FK506 treatment. These data show that systemic FK506 administration, and hence calcineurin inhibition, may be neuroprotective for amyloid beta induced synaptic alterations.
Introduction
Morphological alterations in neurons in the Alzheimer disease (AD) brain including neurite curvature, dystrophic neurite swelling, and synapse and dendritic spines loss are thought to contribute to cognitive decline. In both Alzheimer's disease and mouse models, dendritic spine loss is particularly severe near amyloid plaques, which are composed largely of amyloid beta (Aβ) (Moolman et al., 2004; Spires et al., 2005) . Simplification of the dendritic arbor has also been observed in AD mouse models (Alpar et al., 2006) , which could contribute to dysfunction in learning and memory (Poirazi and Mel, 2001) . Aβ is toxic to synapses and disrupts cognitive function (Cleary et al., 2005; Rowan et al., 2004) , thus it may underlie dendritic spine loss near plaques. Snyder et al. elegantly showed in cultured cortical neurons that Aβ promotes endocytosis of NMDA receptors, and that this requires α7-nAchRs and downstream pathways including calcineurin activation (Snyder et al., 2005) . Although Aβ is a strong candidate for causing synapse loss around plaques, other plaque associated agents could also contribute including free radicals and microglial activation (Garcia-Alloza et al., 2006; Meyer-Luehmann et al., 2008) .
We have recently observed that calcineurin mediates Aβ-induced morphological changes including spine loss and dendritic simplification in cultured neurons and that inhibition of calcineurin in AD model mice with a genetically encoded inhibitor can reverse plaqueassociated pathologic alterations in dendrites and dendritic spines (Wu et al., 2010) . Here we sought to test whether pharmacological inhibition of calcineurin with FK506, a commonly used, FDA approved drug, can also cause recovery of morphological alterations in AD model mice, since this would be a potential route for therapeutic intervention in AD. Our previous study injecting virus into the brain to inhibit calcineurin had beneficial effects but clearly is not a viable therapeutic administration route for humans. It has been reported previously that injection of FK506 has restored some cognitive function in AD mouse models (Dineley et al., 2007) , which could be explained by recovery of dendritic spines. Calcineurin is also known to play critical roles in long term potentiation and long term depression phenomena in slice cultures, and manipulation of calcineurin impacts learning and memory in mouse models (Dineley et al., 2010; Klee et al., 1979; Winder and Sweatt, 2001) .
Calcineurin inhibitor FK506 (tacrolimus), acts via the complex of FK506 and FK506-binding protein binding to calcineurin to prevent calcineurin-mediated dephosphorylation (Schreiber and Crabtree, 1992) . It is a commonly used immunosuppressant to combat graft versus host disease after transplant surgery (Anon. (1994) ); however, serious neurological side effects occur in over 10% of FK506 treated patients including tremor, aphasia, cortical blindness, hallucinations, and memory impairment (Lee et al., 2008; Wijdicks et al., 1994) . Thus Neurobiology of Disease 41 (2011) 650-654 
